Risk factors
Advanced Biomed (ADVB) risk factors
Item 1A of every Advanced Biomed Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2026 10-K risk factors51 risks27 new51 dropped8 reworded
The company abandoned biotechnology and now depends on commercializing FinTruth, with no significant AI revenue yet.
Filed Oct 13, 2026 - FY2025 10-K risk factors75 risks
Advanced Biomed faces extreme concentration risk from cross-strait geopolitical tensions between Taiwan and China impacting R&D. The early-stage cancer diagnostics company has no commercial sales, negative operating cash flows of $5.8 million, and no clinical trials completed.
Filed Oct 08, 2025